Previous studies evaluating MK-2206 anti-tumor efficacy in ALL mainly focused on the absolute effect of the substance, but dose-dependencies and duration of the AKT inhibition remained uninvestigated. This evidence concerns the gene AKT1 and acute lymphoblastic leukemia.